Your AI-Trained Oncology Knowledge Connection!
Panelists discuss how emerging therapies like bispecific antibodies, chimeric antigen receptor (CAR) T cells, and novel drug combinations are reshaping treatment options for patients with relapsed/refractory multiple myeloma (R/R MM) who have exhausted standard approaches.
Panelists discuss how talquetamab demonstrates superior efficacy compared with physician-chosen treatments for patients with heavily pretreated multiple myeloma, with improved progression-free survival and response rates.
Panelists discuss how long-term follow-up data from MajesTEC-1 demonstrates teclistamab’s sustained efficacy and safety profile while identifying optimal candidates based on factors like prior therapy exposure, disease characteristics, and fitness level.
Panelists discuss how teclistamab administration and outcomes vary between academic and community settings, highlighting the need for standardized monitoring protocols, staff education, and communication frameworks to ensure consistent patient care and safety across different practice environments.
Panelists discuss how sequential B-cell maturation agent (BCMA)–targeting therapies can be effective despite potential resistance patterns, with experts evaluating factors like prior response duration, alternative targets like GPRC5D or FcRH5, and patient-specific characteristics when deciding treatment sequencing after CAR T progression.
Panelists discuss how bispecific antibodies targeting B-cell maturation agent, GPRC5D, and FcRH5 are transforming relapsed/refractory multiple myeloma treatment (R/R MM) with promising efficacy, manageable safety profiles, and convenient off-the-shelf administration.
Hematologists gathered to discuss recent updates on bispecific antibodies surrounding patients with relapsed/refractory multiple myeloma.
